Fig. 1From: Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancerCourse of selected laboratory parameters (neutrophils, lymphocytes, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyltransferase) of all nine patients (6 treated for 3 weeks, 3 treated for 9 weeks) in the 2.000 mg dose-group. Arabic figures indicate the number of visitBack to article page